InflaRx (IFRX) News Today $1.65 -0.08 (-4.62%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$1.64 -0.01 (-0.61%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Raymond James Financial Inc. Makes New Investment in InflaRx (NASDAQ:IFRX)Raymond James Financial Inc. bought a new position in InflaRx (NASDAQ:IFRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 638,092 shares of the company's stock, valued atMay 5 at 3:26 AM | marketbeat.comInflaRx (IFRX) Projected to Post Quarterly Earnings on WednesdayInflaRx (NASDAQ:IFRX) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-inflarx-stock/)May 4 at 1:35 AM | marketbeat.comCantor Fitzgerald Forecasts InflaRx FY2025 EarningsInflaRx (NASDAQ:IFRX - Free Report) - Cantor Fitzgerald issued their FY2025 earnings estimates for shares of InflaRx in a report released on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings of ($0.87) per share for the year. Cantor FitzgeraldMay 3 at 8:12 AM | marketbeat.comCantor Fitzgerald Estimates InflaRx FY2025 EarningsMay 3 at 3:09 AM | americanbankingnews.comCantor Fitzgerald Begins Coverage on InflaRx (NASDAQ:IFRX)May 2, 2025 | americanbankingnews.comInflaRx (IFRX) to Release Earnings on WednesdayMay 2, 2025 | americanbankingnews.comCantor Fitzgerald Initiates Coverage on InflaRx (NASDAQ:IFRX)Cantor Fitzgerald started coverage on InflaRx in a report on Tuesday. They set an "overweight" rating and a $10.00 price objective for the company.May 1, 2025 | marketbeat.comInflaRx to Report First Quarter 2025 Results on May 7, 2025 | IFRX Stock NewsApril 30, 2025 | gurufocus.comInflaRx to Report First Quarter 2025 Results on May 7, 2025April 30, 2025 | gurufocus.comInflaRx to Report First Quarter 2025 Results on May 7, 2025April 30, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of InflaRx N.V. (IFRX) with Overweight RecommendationApril 30, 2025 | msn.comBiotech Shares Jump As Institutional Coverage Begins With Positive OutlookApril 29, 2025 | msn.comInflaRx Approves Key Resolutions at Annual Shareholder MeetingApril 24, 2025 | tipranks.comEversept Partners LP Has $1.22 Million Stock Position in InflaRx (NASDAQ:IFRX)Eversept Partners LP lessened its holdings in InflaRx (NASDAQ:IFRX - Free Report) by 69.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 492,452 shares of the company's stock afApril 24, 2025 | marketbeat.comInflaRx (NASDAQ:IFRX) Short Interest Up 36.8% in MarchInflaRx (NASDAQ:IFRX - Get Free Report) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 794,600 shares, a growth of 36.8% from the March 15th total of 581,000 shares. Based on an average daily volume of 391,800 shares, the short-interest ratio is presently 2.0 days. Approximately 1.4% of the shares of the stock are sold short.April 21, 2025 | marketbeat.comInflaRx N.V. Announces 2025 Annual General Meeting AgendaApril 3, 2025 | tipranks.comRaymond James Financial Inc. Purchases Shares of 638,092 InflaRx (NASDAQ:IFRX)Raymond James Financial Inc. acquired a new position in InflaRx (NASDAQ:IFRX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 638,092 shares of the company's stock, valued at approximately $1,576,000.April 3, 2025 | marketbeat.comIs InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?April 2, 2025 | msn.comInflaRx price target raised to $10 from $7 at GuggenheimMarch 27, 2025 | markets.businessinsider.comGuggenheim Raises InflaRx (NASDAQ:IFRX) Price Target to $10.00Guggenheim lifted their target price on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday.March 27, 2025 | marketbeat.comLifeSci Capital Remains a Hold on InflaRx (IFRX)March 22, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for InflaRx (NASDAQ:IFRX)HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of InflaRx in a research report on Friday.March 22, 2025 | marketbeat.comInflaRx N.V. Receives European Commission Approval for GOHIBIC® (vilobelimab) and Achieves Key Development Milestones in Clinical TrialsMarch 22, 2025 | nasdaq.comInflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last yearMarch 21, 2025 | markets.businessinsider.comInflaRx (NASDAQ:IFRX) Posts Quarterly Earnings ResultsInflaRx (NASDAQ:IFRX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%.March 21, 2025 | marketbeat.comPromising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market PotentialMarch 21, 2025 | tipranks.comInflaRx N.V. Reports 2024 Results and Key AchievementsMarch 21, 2025 | tipranks.comInflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected MilestonesMarch 20, 2025 | markets.businessinsider.comInflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected MilestonesMarch 20, 2025 | globenewswire.comShort Interest in InflaRx (NASDAQ:IFRX) Grows By 46.2%InflaRx (NASDAQ:IFRX - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 564,700 shares, a growth of 46.2% from the February 13th total of 386,300 shares. Based on an average trading volume of 382,600 shares, the short-interest ratio is currently 1.5 days. Approximately 1.0% of the shares of the company are sold short.March 16, 2025 | marketbeat.comInflaRx (IFRX) Projected to Post Earnings on ThursdayInflaRx (NASDAQ:IFRX) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for InflaRx (NASDAQ:IFRX)HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of InflaRx in a research note on Friday.March 8, 2025 | marketbeat.comInflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual MeetingMarch 7, 2025 | finance.yahoo.comInflaRx announces presentation of multiple posters on utility of vilobelimabMarch 7, 2025 | markets.businessinsider.comInflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingMarch 7, 2025 | gurufocus.comInflaRx’s Gohibic Gains Momentum with Promising Clinical Data and Regulatory Support, Backing Buy RatingMarch 7, 2025 | tipranks.comInflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingMarch 7, 2025 | globenewswire.comInflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual MeetingFebruary 28, 2025 | finance.yahoo.comInflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingFebruary 28, 2025 | globenewswire.comInflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor ConferencesFebruary 25, 2025 | globenewswire.comInflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 18, 2025 | globenewswire.comShort Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7%InflaRx (NASDAQ:IFRX - Get Free Report) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 415,200 shares, a drop of 13.7% from the January 15th total of 481,300 shares. Based on an average daily trading volume, of 305,500 shares, the short-interest ratio is presently 1.4 days.February 17, 2025 | marketbeat.comInflaRx Shares Drop After Public Offering PricesFebruary 14, 2025 | marketwatch.comInflaRx dips 16%, prices $30M stock offeringFebruary 14, 2025 | msn.comInflaRx announces ordinary shares and warrants offering, no amount givenFebruary 13, 2025 | markets.businessinsider.comInflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 13, 2025 | globenewswire.comInflaRx launches public offering of shares and warrantsFebruary 13, 2025 | msn.comInflaRx Announces Public Offering of Ordinary Shares and Pre-Funded WarrantsFebruary 13, 2025 | globenewswire.comInflaRx (NASDAQ:IFRX) Short Interest UpdateInflaRx (NASDAQ:IFRX - Get Free Report) saw a large increase in short interest in January. As of January 15th, there was short interest totalling 248,900 shares, an increase of 15.0% from the December 31st total of 216,500 shares. Based on an average trading volume of 264,900 shares, the days-to-cover ratio is currently 0.9 days.February 1, 2025 | marketbeat.comInflaRx Announces Participation in Guggenheim SMID Cap Biotech ConferenceJanuary 23, 2025 | globenewswire.com Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IFRX Media Mentions By Week IFRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IFRX News Sentiment▼0.570.72▲Average Medical News Sentiment IFRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IFRX Articles This Week▼162▲IFRX Articles Average Week Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Benitec Biopharma News Today Cartesian Therapeutics News Today MBX Biosciences News Today Septerna News Today Monte Rosa Therapeutics News Today ProKidney News Today Atai Life Sciences News Today Atyr PHARMA News Today Phathom Pharmaceuticals News Today Cryoport News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IFRX) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.